These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10782624)

  • 1. Cost analysis of glaucoma medications.
    Vold SD; Wiggins DA; Jackimiec J
    J Glaucoma; 2000 Apr; 9(2):150-3. PubMed ID: 10782624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost analysis of glaucoma medications: a 3-year review.
    Vold SD; Riggs WL; Jackimiec J
    J Glaucoma; 2002 Aug; 11(4):354-8. PubMed ID: 12169974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical therapy cost considerations for glaucoma.
    Fiscella RG; Green A; Patuszynski DH; Wilensky J
    Am J Ophthalmol; 2003 Jul; 136(1):18-25. PubMed ID: 12834665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost considerations of medical therapy for glaucoma.
    Fiscella RG; Geller JL; Gryz LL; Wilensky J; Viana M
    Am J Ophthalmol; 1999 Oct; 128(4):426-33. PubMed ID: 10577583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost analysis of glaucoma medications.
    Rylander NR; Vold SD
    Am J Ophthalmol; 2008 Jan; 145(1):106-13. PubMed ID: 18154755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily cost of glaucoma medications in China.
    Gao Y; Wu L; Li A
    J Glaucoma; 2007; 16(7):594-7. PubMed ID: 18091176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical glaucoma therapy cost in Mexico.
    Lazcano-Gomez G; Hernandez-Oteyza A; Iriarte-Barbosa MJ; Hernandez-Garciadiego C
    Int Ophthalmol; 2014 Apr; 34(2):241-9. PubMed ID: 23846765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily cost of beta-adrenergic blocker therapy.
    Stewart WC; Sine C; Cate E; Minno GE; Hunt HH
    Arch Ophthalmol; 1997 Jul; 115(7):853-6. PubMed ID: 9230824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daily cost of newer glaucoma agents.
    Stewart WC; Hudgins AC; Pruitt CA; Sine C
    J Ocul Pharmacol Ther; 1999 Oct; 15(5):379-88. PubMed ID: 10530699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two new drugs for glaucoma.
    Med Lett Drugs Ther; 2018 Jul; 60(1551):117-120. PubMed ID: 30036347
    [No Abstract]   [Full Text] [Related]  

  • 12. Costs and persistence of carbonic anhydrase inhibitor versus alpha-2 agonists, associated with beta-blockers, in glaucoma and ocular hypertension: an analysis of the UK-GPRD database.
    Lafuma A; Berdeaux G
    Curr Med Res Opin; 2008 May; 24(5):1519-27. PubMed ID: 18413015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary drug treatment for glaucoma: beta-blockers versus other medications.
    Stamper RL; Wigginton SA; Higginbotham EJ
    Surv Ophthalmol; 2002; 47(1):63-73. PubMed ID: 11801272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario.
    Popovic M; Chan C; Lattanzio N; El-Defrawy S; Schlenker MB
    Can J Ophthalmol; 2018 Apr; 53(2):173-187. PubMed ID: 29631831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.
    Strahlman E; Tipping R; Vogel R
    Arch Ophthalmol; 1995 Aug; 113(8):1009-16. PubMed ID: 7639651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily cost of ophthalmic solutions for treating glaucoma in Japan.
    Ikeda H; Sato E; Kitaura T; Fukuchi H; Kimura Y; Kihira K
    Jpn J Ophthalmol; 2001; 45(1):99-102. PubMed ID: 11163052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications.
    Goldberg LD; Walt J
    Pharmacoeconomics; 2006; 24(3):251-64. PubMed ID: 16519547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effectivity analysis of the most used antiglaucoma drugs].
    Galindo-Ferreiro A; Sánchez-Tocino H; Fernández-Muñoz M; Iglesias Cortiñas D
    Arch Soc Esp Oftalmol; 2004 Aug; 79(8):379-84. PubMed ID: 15306964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost.
    Stewart WC; Day DG; Sharpe ED; Dubiner HB; Holmes KT; Stewart JA
    Am J Ophthalmol; 1999 Dec; 128(6):692-6. PubMed ID: 10612504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care.
    Bateman DN; Clark R; Azuara-Blanco A; Bain M; Forrest J
    Br J Ophthalmol; 2002 May; 86(5):551-4. PubMed ID: 11973253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.